Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Genetics

The Science of Diagnosing LAL-D

At a Glance

Lysosomal Acid Lipase Deficiency (LAL-D) is definitively diagnosed using a Dried Blood Spot (DBS) test, which measures the missing LAL enzyme's activity. Diagnosis is often supported by LIPA gene testing and liver biopsies showing microvesicular steatosis or cholesteryl crystals.

Diagnosing LAL-D requires a combination of blood work, genetic analysis, and sometimes a look at the liver tissue itself. Because LAL-D is an autosomal recessive condition, you must inherit two changed copies of the LIPA gene (one from each parent) to have the disease [1]. Because of this inheritance pattern, coordinating closely with a genetic counselor is a vital step to assess the health of siblings and for family planning.

The Definitive Test: Dried Blood Spot (DBS)

The Dried Blood Spot (DBS) test is the most important step in confirming LAL-D [2].

  • What it measures: This test measures the actual “work” being done by the lysosomal acid lipase enzyme in your white blood cells [3].
  • How it works: A few drops of blood are dried on a special card. In a healthy person, the enzyme will break down a test fat (substrate) at a normal rate. In LAL-D, this activity is either significantly reduced or completely absent [3][4].
  • Why it matters: This test tells your doctor exactly how much residual enzyme activity you have. Infants with Wolman disease usually have less than 1% activity, while those with CESD have a small but measurable amount [5][6].

Genetic Testing: Finding the Mutation

Genetic testing looks at the LIPA gene to find the specific mutations causing the enzyme deficiency [7].

  • E8SJM Mutation: This is the most common mutation found in later-onset LAL-D [1]. Identifying your specific mutation helps your doctor understand your disease and can help screen other family members [8].

Looking at the Liver: Biopsy and Pathology

While blood tests are usually enough to diagnose LAL-D, a liver biopsy (taking a tiny piece of liver tissue) can help show the extent of the damage [9].

  • Microvesicular Steatosis: This is a key finding where liver cells are filled with tiny, uniform droplets of fat [4][10]. This is different from “macrovesicular steatosis” (large fat drops) often seen in common obesity-related fatty liver disease [4].
  • Birefringent Crystals: Under a special “polarized” microscope, doctors can see tiny, glowing crystals made of cholesteryl esters [11]. These crystals are a “smoking gun” for LAL-D—they are almost never seen in any other liver condition [9].

Understanding Your Lab Numbers

You will see several recurring terms in your reports:

  • ALT and AST: These are liver enzymes. When your liver cells are stressed or damaged by fat buildup, these enzymes “leak” into your blood, causing your levels to rise [4].
  • Lipid Panel: This measures fats in your blood. In LAL-D, you will typically see very high LDL (“bad” cholesterol), high triglycerides, and very low HDL (“good” cholesterol) [12][4].

Completeness Checklist

Ensure your diagnostic records include these four critical pieces of data:

  1. Enzyme Activity Level: Usually expressed as a number (nmol/disk/h) from a DBS test [3].
  2. Genetic Variants: The specific names of the two LIPA mutations identified [7].
  3. ALT/AST Baseline: Your liver enzyme levels at the time of diagnosis [4].
  4. Steatosis Type: If a biopsy was done, it should specify microvesicular fat and the presence of birefringent crystals [9][11].

Common questions in this guide

How is LAL-D definitively diagnosed?
The most definitive way to diagnose LAL-D is through a Dried Blood Spot (DBS) test. This simple blood test measures the actual activity level of the lysosomal acid lipase enzyme in your white blood cells.
What does a genetic test for LAL-D look for?
Genetic testing looks for specific mutations in the LIPA gene, such as the common E8SJM mutation. Identifying your exact mutation helps confirm the diagnosis, guides your doctor's understanding of the disease, and assists with family screening.
What do birefringent crystals in a liver biopsy mean?
Finding birefringent crystals under a polarized microscope during a liver biopsy is a strong indicator of LAL-D. These tiny crystals are made of cholesteryl esters and are a hallmark sign that is almost never seen in other liver conditions.
How does LAL-D affect cholesterol levels?
People with LAL-D typically have abnormal lipid panels that may not improve with standard diets or medications. This usually includes very high LDL (bad cholesterol), high triglycerides, and very low HDL (good cholesterol).
What is microvesicular steatosis?
Microvesicular steatosis is a specific type of fat buildup where liver cells become filled with tiny, uniform droplets of fat. This pattern is commonly seen in LAL-D and looks different from the large fat drops found in typical obesity-related fatty liver disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was the exact percentage of LAL enzyme activity found in the Dried Blood Spot (DBS) test?
  2. 2.Does my genetic report show the 'E8SJM' mutation, or a different LIPA variant?
  3. 3.Was 'microvesicular steatosis' or 'birefringent crystals' noted on the pathology report from my liver biopsy?
  4. 4.What are my baseline ALT and AST levels, and how often will we monitor them to track my treatment response?
  5. 5.How do we coordinate genetic testing and carrier screening for my family members?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia.

    Stitziel NO, Fouchier SW, Sjouke B, et al.

    Arteriosclerosis, thrombosis, and vascular biology 2013; (33(12)):2909-14 doi:10.1161/ATVBAHA.113.302426.

    PMID: 24072694
  2. 2

    Diagnostic and therapeutic management of children with lysosomal acid lipase deficiency (LAL-D). Review of the literature and own experience.

    Wierzbicka-Rucińska A, Jańczyk W, Ługowska A, et al.

    Developmental period medicine 2016; (20(3)):212-215.

    PMID: 27941191
  3. 3

    Stratification of patients with lysosomal acid lipase deficiency by enzyme activity in dried blood spots.

    Hong X, Chen Y, Barr M, Gelb MH

    Molecular genetics and metabolism reports 2022; (33()):100935 doi:10.1016/j.ymgmr.2022.100935.

    PMID: 36393897
  4. 4

    Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction.

    Reiner Ž, Guardamagna O, Nair D, et al.

    Atherosclerosis 2014; (235(1)):21-30.

    PMID: 24792990
  5. 5

    A rare cause of hepatomegaly in the childhood: Lysosomal acid lipase deficiency.

    Haznedar P, Kuloğlu Z, Kansu A, Eminoğlu FT

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2018; (29(4)):518-519 doi:10.5152/tjg.2018.17492.

    PMID: 30249571
  6. 6

    Lysosomal acid lipase deficiency in Brazilian children: a case series.

    Benevides GN, Miura IK, Person NC, et al.

    Jornal de pediatria 2019; (95(5)):552-558 doi:10.1016/j.jped.2018.05.016.

    PMID: 31340901
  7. 7

    Lysosomal acid lipase deficiency manifestations in children and adults: Baseline data from an international registry.

    Balwani M, Balistreri W, D'Antiga L, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2023; (43(7)):1537-1547 doi:10.1111/liv.15620.

    PMID: 37222260
  8. 8

    The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: A rare condition that mimics NAFLD.

    Carter A, Brackley SM, Gao J, Mann JP

    Journal of hepatology 2019; (70(1)):142-150 doi:10.1016/j.jhep.2018.09.028.

    PMID: 30315827
  9. 9

    IMPORTANCE OF LIVER BIOPSY IN THE DIAGNOSIS OF LYSOSOMAL ACID LIPASE DEFICIENCY: A CASE REPORT.

    Tommaso AMA, Barra FFC, Hessel G, et al.

    Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo 2018; (36(1)):4 doi:10.1590/1984-0462/;2018;36;1;00016.

    PMID: 29091130
  10. 10

    Differential Diagnosis of a Patient with Lysosomal Acid Lipase Deficiency: A Case Report.

    Akki AS, Chung SM, Rudolph BJ, Ewart MR

    Laboratory medicine 2018; (49(4)):377-384 doi:10.1093/labmed/lmy027.

    PMID: 29982809
  11. 11

    Cholesteryl Ester Crystals in Lysosomal Acid Lipase Deficiency.

    Ivashkin V, Zharkova M

    The New England journal of medicine 2017; (376(9)):e14 doi:10.1056/NEJMicm1610060.

    PMID: 28249129
  12. 12

    Diagnostic Algorithm for Cholesteryl Ester Storage Disease: Clinical Presentation in 19 Polish Patients.

    Lipiński P, Ługowska A, Zakharova EY, et al.

    Journal of pediatric gastroenterology and nutrition 2018; (67(4)):452-457 doi:10.1097/MPG.0000000000002084.

    PMID: 29958253

This page explains diagnostic tests for LAL-D for educational purposes only. Always consult with a genetic counselor or hepatologist for medical advice and to accurately interpret your test results.

Get notified when new evidence is published on Lysosomal acid lipase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.